Skip to main content
Premium Trial:

Request an Annual Quote

Ignyta, Leiden U Medical Center Evaluate Epigenetic Signatures for Synovitis, RA

NEW YORK (GenomeWeb News) – Autoimmune molecular diagnostics firm Ignyta today said it is working with Leiden University Medical Center to evaluate epigenetic signatures of patients with early synovitis and rheumatoid arthritis.

Financial and other terms of the collaboration were not disclosed.

"With the signing of this collaboration with LUMC, Ignyta now has a global reach to study patients with undifferentiated arthritis and rheumatoid arthritis, taking us another step closer to achieving our goal of developing a diagnostic assay for patients with early RA," Jonathan Lim, co-founder, chairman, and CEO of Ignyta, said in a statement.

Based in San Diego, Ignyta was founded in 2011 with technology licensed from the University of California, San Diego. The company was formerly called NexDx. Last month, it announced it raised $5.5 million in an expanded Series B financing round.

The Scan

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.

Clinical Genomic Lab Survey Looks at Workforce Needs

Investigators use a survey approach in Genetics in Medicine Open to assess technologist applications, retention, and workforce gaps at molecular genetics and clinical cytogenetics labs in the US.

Study Considers Gene Regulatory Features Available by Sequence-Based Modeling

Investigators in Genome Biology set sequence-based models against observational and perturbation assay data, finding distal enhancer models lag behind promoter predictions.

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.